RxDoctor Payments Data

Scott Dean, MD

Nephrology · Panama City, FLNPI 1629074919

Payments from drug & device makers

$97,152in general payments, 2019–2025

Across 347 payments — averaging $279.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$44K
  • Calliditas Therapeutics US Inc.$42K
  • Vifor Pharma, Inc.$7K
  • Otsuka America Pharmaceutical, Inc.$478
  • OPKO Pharmaceuticals, LLC$444
  • Amgen$389
  • plus $3K from 26 others

What the payments were for

  • Consulting fees$3,6004%
  • Speaking & faculty fees$78,56381%
  • Travel & lodging$7,1607%
  • Food & beverage$7,7338%
  • Education$960%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$97,152 in reported general payments places this provider in the 85th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$237,164
Medicare patients
424
Services billed
1,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol469$530,679
JardianceEmpagliflozin242$303,527
VeltassaPatiromer Calcium Sorbitex32$43,949
VelphoroSucroferric Oxyhydroxide16$39,137
KerendiaFinerenone18$28,918
LokelmaSodium Zirconium Cyclosilicate18$15,582
Cinacalcet Hcl17$6,186
DapagliflozinDapagliflozin Propanediol12$5,953
Sevelamer Carbonate21$5,856
Telmisartan156$5,065
Chlorthalidone190$3,715
Amlodipine Besylate295$2,194
Atorvastatin Calcium223$1,692
Calcitriol102$1,682
Calcium Acetate21$1,441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$43,927$546,261487 claims
Boehringer IngelheimJardiance$24$303,527242 claims
Fresenius USA Marketing, Inc.Velphoro$383$39,13716 claims
BayerKerendia$273$28,91818 claims
ANI Pharmaceuticals, Inc.Valsartan$247$35717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 756 nephrology providers in Florida.

Other nephrology in Panama City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →